

# Detection of circulating epithelial tumour cells (DETECT)

<b>Submission date</b> 17/04/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 04/05/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 22/08/2012	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

**Study website**  
<http://www.detetct-study.de>

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Tanja Fehm

**Contact details**  
Dept of Gynaecology and Obstetrics  
Calwer Str 7  
Tuebingen  
Germany  
72076

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
DETECT 1

# Study information

## Scientific Title

A comparison of an antibody-based and an RT-PCR-based technique for the detection of circulating epithelial tumour cells: A multicentre, observational study

## Acronym

DETECT

## Study objectives

The aim of this prospective multi-centre trial was to compare the HER2 status of circulating tumour cells (CTCs) in 254 metastatic breast cancer patients at the time of first diagnosis or disease progression obtained by the antibody-based CellSearch® assay and the RT-PCR approach AdnaTest™ Breast Cancer and to assess the concordance rate between these two techniques.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

The local institutional review board of the University of Tuebingen, Germany approved on the 26th of September 2007 (ref: 2007/B01).

## Study design

Prospective multicentre open label non-randomised observational trial

## Primary study design

Observational

## Secondary study design

Non randomised controlled trial

## Study setting(s)

Other

## Study type(s)

Diagnostic

## Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Metastatic breast cancer

## Interventions

Metastatic breast cancer patients were enrolled in this prospective open non-randomized and non-interventional study. Blood was drawn before the start of a new line of therapy.

1. Blood sampling mandatory (one or two times 50mL)
2. Bone marrow aspiration (not mandatory)

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

Rate of HER2 positive CTCs with each method

**Secondary outcome measures**

Concordance between the two methods in (HER2 positive) CTC detection

**Overall study start date**

01/12/2007

**Completion date**

01/04/2009

**Eligibility****Key inclusion criteria**

1. Epithelial invasive carcinoma of the breast with distant metastatic disease (M1)
2. Age  $\leq$  18 years
3. First diagnosis of metastatic disease or disease progression (before start of new treatment regimen)
4. Written informed consent

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Female

**Target number of participants**

254

**Key exclusion criteria**

Secondary primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)

**Date of first enrolment**

01/12/2007

**Date of final enrolment**

01/04/2009

## **Locations**

**Countries of recruitment**

Germany

**Study participating centre**

**Dept of Gynaecology and Obstetrics**

Tuebingen

Germany

72076

## **Sponsor information**

**Organisation**

University of Tuebingen (Germany)

**Sponsor details**

c/o Prof. Dr. Tanja Fehm

Dept. of Gynaecology and Obstetrics

Calwer Str 7

Tuebingen

Germany

72076

**Sponsor type**

University/education

**ROR**

<https://ror.org/03a1kwz48>

## **Funder(s)**

**Funder type**

Hospital/treatment centre

**Funder Name**

Institutional funding of participating centres (Germany)

**Funder Name**

Roche Pharma GmbH (Germany)

**Funder Name**

Adnagen GmbH (Germany)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/11/2010		Yes	No
<a href="#">Results article</a>	results	11/07/2011		Yes	No